Wall Street Zen Upgrades PainReform (NASDAQ:PRFX) to “Hold”

PainReform (NASDAQ:PRFX) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research note issued to investors on Friday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of PainReform in a research note on Saturday, September 27th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce”.

PainReform Stock Performance

Shares of PRFX opened at $1.38 on Friday. The stock has a 50-day simple moving average of $1.46 and a 200-day simple moving average of $1.75. The stock has a market capitalization of $2.77 million, a PE ratio of -0.01 and a beta of 0.58. PainReform has a 1 year low of $1.25 and a 1 year high of $16.63.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.